A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma

Protocol: 
AAAO5917
Phase: 
II

A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma

The purpose of this research study is to find out what effects, good and/or bad, vorinostat has on you and your uveal melanoma. Vorinostat is approved by the FDA for the treatment of certain lymphomas of the skin. Vorinostat treatment for uveal melanoma is experimental. Vorinostat is a medication that blocks a protein called histone deacetylase. In laboratory experiments, uveal melanoma cells stop growing and die after blocking histone deacetylase with vorinostat. We now want to see if vorinostat will result in tumor shrinkage in patients with uveal melanoma.

Are you Eligible? (Inclusion Criteria)

1. Patients must have metastic histologically or cytologically confirmed uveal melanoma.
2. Patients must have measureable disease as defined by RECIST v 1.1
3. 18 or older
4. Tumor GNAQ, GNA11, and BAP1 mutational status must be determined on all patients.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States